Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis

A Sandoo; V F Panoulas; T E Toms; J P Smith; A Stavropoulos-Kalinoglou; G S Metsios; A Y Gasparyan; D Carroll; J J C S Veldhuijzen van Zanten; G D Kitas

doi:10.1038/jhh.2011.36

Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis

A Sandoo
, V F Panoulas
, T E Toms
, J P Smith
, A Stavropoulos-Kalinoglou
, G S Metsios
, A Y Gasparyan
, D Carroll
, J J C S Veldhuijzen van Zanten
, G D Kitas

Dudley Group NHS, Dudley

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	699-702
Number of pages	4
Journal	Journal of human hypertension
Volume	25
Issue number	11
DOIs	https://doi.org/10.1038/jhh.2011.36
Publication status	Published - Nov 2011
Externally published	Yes

Keywords

Adalimumab
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antirheumatic Agents
Arthritis, Rheumatoid
Blood Pressure
Endothelium, Vascular
England
Etanercept
Humans
Immunoglobulin G
Inflammation Mediators
Infliximab
Longitudinal Studies
Microvessels
Receptors, Tumor Necrosis Factor
Time Factors
Treatment Outcome
Tumor Necrosis Factor-alpha
Letter
Research Support, Non-U.S. Gov't

Access to Document

10.1038/jhh.2011.36

Cite this

Sandoo, A., Panoulas, V. F., Toms, T. E., Smith, J. P., Stavropoulos-Kalinoglou, A., Metsios, G. S., Gasparyan, A. Y., Carroll, D., Veldhuijzen van Zanten, J. J. C. S., & Kitas, G. D. (2011). Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis. Journal of human hypertension, 25(11), 699-702. https://doi.org/10.1038/jhh.2011.36

@article{958bb49192a7470ea4a075ae22f31972,

title = "Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis",

keywords = "Adalimumab, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Arthritis, Rheumatoid, Blood Pressure, Endothelium, Vascular, England, Etanercept, Humans, Immunoglobulin G, Inflammation Mediators, Infliximab, Longitudinal Studies, Microvessels, Receptors, Tumor Necrosis Factor, Time Factors, Treatment Outcome, Tumor Necrosis Factor-alpha, Letter, Research Support, Non-U.S. Gov't",

author = "A Sandoo and Panoulas, \{V F\} and Toms, \{T E\} and Smith, \{J P\} and A Stavropoulos-Kalinoglou and Metsios, \{G S\} and Gasparyan, \{A Y\} and D Carroll and \{Veldhuijzen van Zanten\}, \{J J C S\} and Kitas, \{G D\}",

year = "2011",

month = nov,

doi = "10.1038/jhh.2011.36",

language = "English",

volume = "25",

pages = "699--702",

journal = "Journal of human hypertension",

issn = "0950-9240",

publisher = "Springer Nature",

number = "11",

}

Sandoo, A, Panoulas, VF, Toms, TE, Smith, JP, Stavropoulos-Kalinoglou, A, Metsios, GS, Gasparyan, AY, Carroll, D, Veldhuijzen van Zanten, JJCS & Kitas, GD 2011, 'Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis', Journal of human hypertension, vol. 25, no. 11, pp. 699-702. https://doi.org/10.1038/jhh.2011.36

TY - JOUR

T1 - Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis

AU - Sandoo, A

AU - Panoulas, V F

AU - Toms, T E

AU - Smith, J P

AU - Stavropoulos-Kalinoglou, A

AU - Metsios, G S

AU - Gasparyan, A Y

AU - Carroll, D

AU - Veldhuijzen van Zanten, J J C S

AU - Kitas, G D

PY - 2011/11

Y1 - 2011/11

KW - Adalimumab

KW - Antibodies, Monoclonal

KW - Antibodies, Monoclonal, Humanized

KW - Antirheumatic Agents

KW - Arthritis, Rheumatoid

KW - Blood Pressure

KW - Endothelium, Vascular

KW - England

KW - Etanercept

KW - Humans

KW - Immunoglobulin G

KW - Inflammation Mediators

KW - Infliximab

KW - Longitudinal Studies

KW - Microvessels

KW - Receptors, Tumor Necrosis Factor

KW - Time Factors

KW - Treatment Outcome

KW - Tumor Necrosis Factor-alpha

KW - Letter

KW - Research Support, Non-U.S. Gov't

U2 - 10.1038/jhh.2011.36

DO - 10.1038/jhh.2011.36

M3 - Article

C2 - 21525886

SN - 0950-9240

VL - 25

SP - 699

EP - 702

JO - Journal of human hypertension

JF - Journal of human hypertension

IS - 11

ER -